Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Over the last 12 months, insiders at Zai Lab Limited have bought $380,940 and sold $1.7M worth of Zai Lab Limited stock.
On average, over the past 5 years, insiders at Zai Lab Limited have bought $333,190 and sold $60.15M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Smiley Joshua L (See Remarks) — $761,880.
The last purchase of 3,000 shares for transaction amount of $64,200 was made by Smiley Joshua L (See Remarks) on 2024‑05‑13.
2024-05-14 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 10,000 0.01% | $21.33 | $213,346 | -11.71% | |
2024-05-13 | Smiley Joshua L | See Remarks | 3,000 0.003% | $21.40 | $64,200 | -11.38% | ||
2024-04-04 | Sale | Reinhart Harald | See Remarks | 2,105 0.0022% | $15.67 | $32,992 | +16.54% | |
2024-04-04 | Sale | Smiley Joshua L | See Remarks | 1,988 0.002% | $15.67 | $31,158 | +16.54% | |
2024-04-04 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 1,244 0.0013% | $15.67 | $19,497 | +16.54% | |
2024-04-04 | Sale | Amado Rafael | See Remarks | 1,952 0.002% | $15.67 | $30,594 | +16.54% | |
2024-04-04 | Sale | Chen Yajing | Chief Financial Officer | 845 0.0009% | $15.67 | $13,244 | +16.54% | |
2024-04-02 | Sale | Du Ying | Chairperson & CEO | 5,787 0.0059% | $16.15 | $93,466 | +12.00% | |
2024-04-02 | Sale | Reinhart Harald | See Remarks | 1,773 0.0018% | $16.15 | $28,636 | +12.00% | |
2024-04-02 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 885 0.0009% | $16.15 | $14,294 | +12.00% | |
2024-04-02 | Sale | Chen Yajing | Chief Financial Officer | 519 0.0005% | $16.15 | $8,382 | +12.00% | |
2024-03-15 | Sale | Amado Rafael | See Remarks | 2,544 0.0026% | $18.86 | $47,980 | -6.66% | |
2024-03-15 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 10,000 0.0103% | $18.71 | $187,127 | -6.66% | |
2024-03-01 | Smiley Joshua L | See Remarks | 3,000 0.0029% | $20.83 | $62,490 | -14.56% | ||
2024-01-03 | Sale | Du Ying | Chairperson & CEO | 8,380 0.008% | $26.12 | $218,902 | -26.93% | |
2024-01-03 | Sale | Reinhart Harald | See Remarks | 4,803 0.0046% | $26.12 | $125,464 | -26.93% | |
2024-01-03 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 4,803 0.0046% | $26.12 | $125,464 | -26.93% | |
2024-01-02 | Sale | Amado Rafael | See Remarks | 19,363 0.0199% | $26.30 | $509,169 | -26.41% | |
2023-12-14 | Smiley Joshua L | See Remarks | 4,000 0.0046% | $29.90 | $119,600 | -34.64% | ||
2023-11-16 | Smiley Joshua L | See Remarks | 5,000 0.0052% | $26.93 | $134,650 | -24.39% |
Du Ying | Chairperson & CEO | 1107972 1.1039% | $17.97 | 0 | 17 | |
Reinhart Harald | See Remarks | 51800 0.0449% | $17.97 | 0 | 17 | |
Edmondson Frazor Titus III | Chief Legal Officer | 16408 0.0292% | $17.97 | 0 | 6 | |
Amado Rafael | See Remarks | 23532 0.022% | $17.97 | 0 | 3 | |
Smiley Joshua L | See Remarks | 31684 0.02% | $17.97 | 4 | 1 | |
Chen Yajing | Chief Financial Officer | 9618 0.0068% | $17.97 | 0 | 3 | |
Fu Tao | President & COO | 77500 0.0755% | $17.97 | 0 | 9 | |
DIEKMAN JOHN D | director | 67615 0.0658% | $17.97 | 0 | 4 | |
Cho William Ki Chul | Chief Financial Officer | 50000 0.0487% | $17.97 | 0 | 2 | |
Chen Kai-Xian | director | 24662 0.024% | $17.97 | 0 | 1 | |
Lis William | director | 23330 0.0227% | $17.97 | 0 | 2 | |
WIRTH PETER | director | 0 0% | $17.97 | 1 | 1 | <0.0001% |
Wellington Management Company | $106.66M | 6.71 | 6.66M | +24.76% | +$21.17M | 0.02 | |
Capital World Investors | $91.06M | 5.73 | 5.68M | +8.92% | +$7.45M | 0.02 | |
Janus Henderson | $70.92M | 4.46 | 4.43M | +9.6% | +$6.21M | 0.04 | |
Woodline Partners LP | $41.6M | 2.62 | 2.6M | +28.65% | +$9.26M | 0.39 | |
Viking Global Investors | $32.81M | 2.06 | 2.05M | +9.57% | +$2.87M | 0.01 | |
T. Rowe Price | $26.45M | 1.66 | 1.65M | -38.96% | -$16.88M | <0.01 | |
Bamco | $25.63M | 1.61 | 1.6M | +7.31% | +$1.75M | 0.07 | |
Segantii Capital Management Cayman Ltd | $24.93M | 1.57 | 1.56M | -7.8% | -$2.11M | 3 | |
Fidelity Investments | $22.5M | 1.42 | 1.4M | +13.54% | +$2.68M | <0.01 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $20.78M | 1.31 | 1.3M | +14.08% | +$2.56M | 0.53 | |
ClearBridge Investments | $13.02M | 0.82 | 812,579 | -1.31% | -$173,352.43 | 0.01 | |
Capital International Investors | $12.92M | 0.81 | 806,453 | 0% | +$0 | <0.01 | |
Legal & General | $12.68M | 0.8 | 793,314 | -4.93% | -$657,470.65 | <0.01 | |
Allianz Asset Management Gmbh | $11.6M | 0.73 | 723,846 | +6.52% | +$710,038.44 | 0.02 | |
Citadel Advisors LLC | $10.58M | 0.67 | 660,574 | +2,059.44% | +$10.09M | 0.01 | |
BlackRock | $10.4M | 0.65 | 649,275 | +15.81% | +$1.42M | <0.0001 | |
State Street | $10.2M | 0.64 | 636,732 | -3.5% | -$369,629.47 | <0.0001 | |
Candriam S C A | $8.57M | 0.54 | 535,013 | +64.61% | +$3.36M | 0.06 | |
Vivo Capital | $8.51M | 0.54 | 531,198 | +29.03% | +$1.91M | 0.75 | |
Brilliance Asset Management Ltd | $6.98M | 0.44 | 435,926 | 0% | +$0 | 1.54 | |
Millennium Management LLC | $6.43M | 0.41 | 401,659 | +60.37% | +$2.42M | 0.01 | |
Connor Clark & Lunn Investment Management Ltd | $5.88M | 0.37 | 366,920 | +81.85% | +$2.65M | 0.01 | |
Goldman Sachs | $4.78M | 0.3 | 298,581 | +99.98% | +$2.39M | <0.01 | |
Russell Investments Group Ltd | $3.65M | 0.3 | 293,783 | +51.1% | +$1.24M | 0.01 | |
Morgan Stanley | $4.24M | 0.27 | 264,709 | -9.02% | -$420,156.52 | <0.0001 | |
Privium Fund Management | $3.86M | 0.24 | 240,683 | 0% | +$0 | 1.13 | |
Schonfeld Group | $3.58M | 0.23 | 223,746 | New | +$3.58M | 0.03 | |
Td Asset Management Inc | $3.51M | 0.22 | 218,970 | -7.05% | -$265,931.97 | <0.01 | |
Genesis Investment Management, LLP | $3.46M | 0.22 | 216,123 | -68.8% | -$7.63M | 0.72 | |
Bank of America | $2.46M | 0.16 | 153,414 | +91.77% | +$1.18M | <0.0001 | |
Schroder Investment Management Group | $2.31M | 0.15 | 144,460 | +82.96% | +$1.05M | <0.01 | |
AllianceBernstein | $2.32M | 0.15 | 144,805 | +95.93% | +$1.14M | <0.01 | |
Jane Street Capital | $2.09M | 0.13 | 130,419 | -15.23% | -$375,268.43 | <0.01 | |
Fil Ltd | $2.02M | 0.13 | 125,941 | -68.07% | -$4.3M | <0.01 | |
Mirae Asset Global Investments Co Ltd | $1.81M | 0.11 | 104,282 | -8.86% | -$175,582.52 | <0.01 | |
Polar Capital | $1.63M | 0.1 | 101,961 | 0% | +$0 | 0.01 | |
The Manufacturers Life Insurance Company | $1.58M | 0.1 | 98,570 | 0% | +$0 | <0.01 | |
Capital Group International Inc Ca | $1.48M | 0.09 | 92,108 | +6.74% | +$93,156.29 | 0.02 | |
UBS | $1.33M | 0.08 | 82,783 | +231.76% | +$926,436.84 | <0.0001 | |
AXA | $1.2M | 0.08 | 74,940 | -51.89% | -$1.29M | <0.01 | |
Alps Advisors Inc | $1.12M | 0.07 | 69,795 | +4.39% | +$47,050.74 | <0.01 | |
Handelsbanken | $1.1M | 0.07 | 68,685 | 0% | +$0 | 0.01 | |
Trexquant Investment LP | $1.07M | 0.07 | 67,045 | +220.53% | +$738,970.63 | 0.01 | |
Aviva | $950,467.00 | 0.06 | 59,330 | 0% | +$0 | <0.01 | |
HSBC | $884,619.00 | 0.06 | 55,462 | -3.29% | -$30,081.70 | <0.01 | |
Geode Capital Management | $876,470.00 | 0.06 | 54,711 | +0.48% | +$4,165.20 | <0.0001 | |
Credit Suisse | $837,894.00 | 0.05 | 52,303 | New | +$837,894.00 | <0.01 | |
Robeco Institutional Asset Management B.V. | $848,868.00 | 0.05 | 52,988 | -10.19% | -$96,280.23 | <0.01 | |
Balyasny Asset Management Llc | $789,466.00 | 0.05 | 49,280 | New | +$789,466.00 | <0.01 | |
New York State Common Retirement Fund | $762,000.00 | 0.05 | 47,557 | +41.76% | +$224,464.49 | <0.01 |